Forte Biosciences (FBRX) Share-based Compensation (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Share-based Compensation data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 96.11% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 99.87% increase from a year earlier, with the FY2025 full-year figure at $14.4 million, up 365.27% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.2 million, up from $1.7 million in the prior quarter.
• Over the last five years, Share-based Compensation for FBRX reached as high as $3.2 million in Q1 2026 and fell as low as $158000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $1.1 million across 5 years, with a median of $860000.0 in 2022.
• Across the five-year window, Share-based Compensation sank 68.08% in 2022 and soared 455.06% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $860000.0 in 2022, then slipped by 9.3% to $780000.0 in 2023, then declined by 10.64% to $697000.0 in 2024, then surged by 138.74% to $1.7 million in 2025, then soared by 90.93% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.2 million in Q1 2026, $1.7 million in Q4 2025, and $1.5 million in Q3 2025.